Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome

Efe E., Kocayigit I., Turker P. M., Murat K., Erkan A., Sedat T., ...More

INDIAN JOURNAL OF PHARMACOLOGY, vol.48, no.4, pp.355-359, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.4103/0253-7613.186205
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.355-359
  • Keywords: Acute coronary syndrome, clopidogrel, drug resistance, lymphocyte, neutrophil, platelet, MYOCARDIAL-INFARCTION, PROGNOSTIC MARKER, ASPIRIN, ASSOCIATION, RESISTANCE, COUNT, INTERVENTION, AGGREGATION, SEVERITY, DEATH
  • Dokuz Eylül University Affiliated: Yes


Objectives: Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-stay treatment of acute coronary syndromes (ACS). However, major adverse cardiovascular events may occur even in patients undergoing DAPT, and this has been related to the variable pharmacodynamic efficacy of these drugs, especially clopidogrel. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers for cardiovascular risk stratification, which may reflect an inflammatory state and thus high on-treatment platelet reactivity (HPR).